MoonLake rebounds despite downgrades prompted by trial setback
Source: SeekingAlpha
2025-09-30 13:34:03 ET
More on MoonLake Immunotherapeutics
- MoonLake: From 'Best-In-Class' Hopes To Approvability Debate (Rating Downgrade)
- MoonLake Immunotherapeutics (MLTX) RND Day Conference Call (Transcript)
- MoonLake Immunotherapeutics (MLTX) RND Day Conference Presentation - Slideshow
- MoonLake plunges after mixed results from skin disease trial
- Goldman's 48 potential M&A candidates
Read the full article on Seeking Alpha
For further details see:
MoonLake rebounds despite downgrades prompted by trial setback
UCB SA
NASDAQ: UCBJF
UCBJF Trading
0.0% G/L:
$299.45 Last:
1 Volume:
$299.45 Open:
